ResMed Inc (RMD)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE
Market Cap: $33.69B
Last updated: Nov 17, 2026 at 4:33 PM ET
ResMed Inc (RMD) Statistics
ResMed (RMD) has a market cap of $33.69B and an enterprise value of $33.09B. Its return on invested capital of 24.25% compares with a 4.43% median across 10 similar companies. Its trailing P/E of 20.6x is below its 10-year median of 30.0x.
Total Valuation
Enterprise value is 1.78% below the market cap, as cash exceeds debt.
| Market Cap | $33.69B |
|---|---|
| Enterprise Value | $33.09B |
| Latest price (Nov 17, 2026) | $237.95 |
Key Dates
The next earnings report is expected on Jan 27, 2027, covering the quarter ending Dec 31, 2026. The last ex-dividend date was Nov 12, 2026.
| Next Earnings Date | Jan 27, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 29, 2026 |
| Last Ex-Dividend Date | Nov 12, 2026 |
| Next Payment Date | Dec 17, 2026 |
| Fiscal Year End | June |
Valuation Ratios
Sales and book value multiples are 5.9x and 5.7x. Its year-end P/E ranged from 22.4x to 46.3x from 2016 to 2025.
| P/E Ratio | 20.6x |
|---|---|
| Forward P/E | 19.4x |
| P/S Ratio | 5.9x |
| Forward P/S | 5.8x |
| P/B Ratio | 5.7x |
| P/TBV Ratio | 13.1x |
| P/FCF Ratio | 21.1x |
| P/OCF Ratio | 19.0x |
| PEG Ratio | 2.4 |
Enterprise Valuation
Counting debt and cash, the company is valued at 15.3x EBITDA and 20.8x free cash flow.
| EV / Earnings | 20.8x |
|---|---|
| EV / Sales | 5.8x |
| EV / EBITDA | 15.3x |
| EV / FCF | 20.8x |
Price Statistics
The stock is down 2.14% over 52 weeks and trades 2.52% above its 50-day average.
| Beta (1Y) | 0.49 |
|---|---|
| 52-Week Change | -2.14% |
| 1-Month Change | -0.48% |
| 3-Month Change | +3.75% |
| 6-Month Change | +14.85% |
| 5-Year Change | -12.54% |
| 10-Year Change | +284.71% |
| Total Return (1Y) | -1.10% |
| Total Return (3Y CAGR) | +17.82% |
| Total Return (5Y CAGR) | -1.18% |
| Return vs SPY (1Y) | -14.39% |
| Max Drawdown (1Y) | -33.58% |
| Max Drawdown (3Y) | -37.45% |
| Sharpe Ratio (1Y) | -0.09 |
| Correlation with SPY (1Y) | 0.22 |
| 50-Day Average | $232.10 |
| 200-Day Average | $222.83 |
| 52-Week Range | $179.26 to $274.65 |
| RSI (14 Days) | 51.2 |
| Average Volume (20 Days) | 1.44M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.65x current liabilities, and total debt is 0.07x shareholder equity.
| Current Ratio | 2.65x |
|---|---|
| Quick Ratio | 1.88x |
| Debt / Equity | 0.07x |
| Debt / EBITDA | 0.19x |
| Debt / FCF | 0.25x |
Returns and Efficiency
Return on invested capital is 24.25% over the last 12 months, against a 5-year average of 19.36%.
| Return on Equity (ROE) | 26.79% |
|---|---|
| Return on Assets (ROA) | 19.40% |
| Return on Invested Capital (ROIC) | 24.25% |
| ROE (5Y Average) | 22.50% |
| ROA (5Y Average) | 15.51% |
| ROIC (5Y Average) | 19.36% |
| Asset Turnover | 0.69x |
| Inventory Turnover | 2.27x |
| Receivables Turnover | 5.71x |
| Cash Conversion Cycle | 173 days |
Taxes
Income tax took 20.81% of pretax income over the last 12 months.
| Income Tax (TTM) | $418.61M |
|---|---|
| Effective Tax Rate | 20.81% |
Scores
RMD has an Altman Z-Score of 12.11, in the safe zone above 2.99, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 12.11 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 7 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $5.73B over the last 12 months is up 9.04% from the 12 months before.
| Revenue | $5.73B |
|---|---|
| Revenue Growth (YoY) | +9.04% |
| Gross Profit | $3.50B |
| Operating Income | $1.89B |
| Pretax Income | $2.01B |
| Net Income | $1.59B |
| EBITDA | $2.19B |
| Reported EPS (TTM) | $11.53 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 72.47% of the $8.21B in total assets.
| Cash and Equivalents | $1.01B |
|---|---|
| Total Debt | $409.60M |
| Net Cash | $601.14M |
| Net Cash Per Share | $4.20 |
| Working Capital | $2.18B |
| Shareholder Equity | $5.95B |
| Book Value Per Share | $41.60 |
| Tangible Book Value | $2.60B |
| Tangible Book Per Share | $18.16 |
| Total Assets | $8.21B |
| Total Liabilities | $2.26B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $162.06M of capital spending, operating cash flow left $1.61B of free cash flow.
| Operating Cash Flow | $1.77B |
|---|---|
| Capital Expenditures | $162.06M |
| Free Cash Flow | $1.61B |
| FCF Per Share | $11.44 |
| Depreciation and Amortization | $238.31M |
| Dividends Paid | $356.87M |
| Share Repurchases | $1.49B |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 33.02%, against a 5-year average of 29.81%.
| Gross Margin | 61.08% |
|---|---|
| Operating Margin | 33.02% |
| Pretax Margin | 35.09% |
| Net Margin | 27.79% |
| EBITDA Margin | 38.12% |
| FCF Margin | 28.06% |
| Gross Margin (5Y Average) | 57.89% |
| Operating Margin (5Y Average) | 29.81% |
| Net Margin (5Y Average) | 23.80% |
Growth
Revenue grew 10.21% a year over 3 years, and EPS 20.09% a year.
| Revenue Growth (3Y CAGR) | +10.21% |
|---|---|
| Revenue Growth (5Y CAGR) | +12.08% |
| EPS Growth (3Y CAGR) | +20.09% |
| EPS Growth (5Y CAGR) | +15.95% |
| FCF Growth (3Y CAGR) | +42.20% |
| FCF Growth (5Y CAGR) | +21.07% |
| Operating Income Growth (3Y CAGR) | +18.57% |
Dividends and Yields
RMD pays out 20.35% of earnings as dividends.
| Dividend Per Share (Annual) | $2.64 |
|---|---|
| Dividend Yield | 1.11% |
| Payment Schedule | Quarterly |
| Dividend Growth (3Y CAGR) | +9.53% |
| Dividend Growth (5Y CAGR) | +7.70% |
| Payout Ratio | 20.35% |
| FCF Payout Ratio | 22.18% |
| Earnings Yield | 4.85% |
| FCF Yield | 4.73% |
| Buyback Yield | 4.16% |
| Shareholder Yield | 5.21% |
Stock Splits
The last split was a 2-for-1 forward split on Aug 31, 2010.
| Last Split Date | Aug 31, 2010 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 2:1 |
Peer Position
Against 11 similar companies, RMD has the 8th highest P/E.
P/E RatioPeer median 20.7x
P/S RatioPeer median 3.0x
ROICPeer median 4.43%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +10.72%
Dividend YieldPeer median 0.00%
| P/E Ratio | 20.6x vs 20.7x median |
|---|---|
| P/S Ratio | 5.9x vs 3.0x median |
| ROIC | 24.25% vs 4.43% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +9.04% vs +10.72% median |
| Dividend Yield | 1.11% vs 0.00% median |
Analyst Forecast
Consensus estimates put revenue growth at 4.77% and EPS growth at 8.82% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +4.77% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +8.82% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About RMD
What is RMD's market cap?
ResMed has a market cap of $33.69B. Its enterprise value, which adds debt and subtracts cash, is $33.09B.
What is RMD's P/E ratio?
ResMed has a trailing P/E ratio of 20.6x and a forward P/E of 19.4x.
How many shares of RMD are outstanding?
ResMed has 142.99M shares outstanding. The count is down 2.18% from a year earlier.
Does RMD pay a dividend?
Yes. ResMed pays $2.64 a share a year, a dividend yield of 1.11%.
How much debt does RMD have?
ResMed has $409.60M of total debt and $1.01B of cash and equivalents, a net cash position of $601.14M.
RMD pages: Overview, Dividends, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors